SB 1713 establishes a new performance-based procurement system called the "Arizona hybrid model" for Arizona's Medicaid program (AHCCCS). It directly affects managed care organizations (MCOs) contracted to provide services under AHCCCS by replacing traditional requests for proposals with a standardized evaluation system. The bill requires all MCOs to be assessed over a four-year performance period using publicly available, measurable metrics covering care access, claims processing, and member experience, with decisions on contract continuation based solely on this scoring. It also mandates a single statewide master contract for all MCOs serving AHCCCS programs, eliminating duplicate contracts and reducing administrative burden.
SB 1188 automatically aligns Arizona's controlled substance scheduling with federal classifications for FDA-approved medications (excluding Schedule I drugs), meaning Arizona will adopt the same schedules as the U.S. Drug Enforcement Administration without requiring separate state action. This allows healthcare providers in Arizona to prescribe these medications as permitted under federal law, eliminating the need for the state pharmacy board to reclassify them. The bill directly affects the Arizona State Board of Pharmacy and medical professionals who prescribe or dispense controlled substances by simplifying scheduling requirements. It applies only to drugs approved by the FDA and scheduled by the federal government (other than Schedule I), ensuring consistency with federal regulations.
HB 2960 establishes a grant program to fund specialized veterans' courts in Arizona counties and municipalities. It creates a "veterans' treatment court fund" using state appropriations, providing money to local governments to set up courts that address veterans' justice-involved behavior through individualized treatment plans for issues like PTSD, substance abuse, and traumatic brain injury. The program requires grantees to report annually on participant demographics, recidivism, treatment use, and program outcomes, with the Attorney General compiling statewide data and recommendations for improvement. This directly affects veterans involved in the criminal justice system by connecting them to targeted support services rather than standard court processing.
SB 1630 establishes a new Arizona Medicaid program providing home and community-based services for adults with serious mental illness, replacing institutional care when possible. It sets eligibility based on clinical criteria (like recent hospitalizations, medication complexity, or safety risks) and income limits (300% of federal SSI), with options for a qualified income trust to meet financial requirements. Covered services include personal care, medication management, supervised community living, adult day health, and nonemergency transportation. The program requires federal approval by 2027 and aims to support individuals in community settings while avoiding psychiatric hospital or residential facility placement.
SB 1814 establishes a temporary study committee to examine Arizona's substance use disorder treatment system. The committee, composed of legislators, health officials, clinicians, and individuals with lived experience, will study treatment availability, gaps in care, regulatory loopholes, and workforce needs. It must report by December 31, 2027, with recommendations for evidence-based standards, oversight reforms, and funding strategies. The committee expires on June 30, 2028, and does not enact new laws.
SB 1214 restricts Arizona physicians from using stem cells or birth tissue derived from aborted fetuses or embryos for therapy. It allows non-FDA-approved stem cell or birth tissue therapies only for orthopedics, wound care, or pain management, provided the cells come from FDA-registered or certified facilities (like blood banks or tissue banks) and meet specific safety and viability standards. The bill requires physicians to disclose in advertising and obtain detailed informed consent stating the therapy isn't FDA-approved, and mandates facilities to provide full certification details to physicians. These provisions directly affect medical providers, clinics, and tissue suppliers offering such therapies in Arizona.
SB 1235 establishes Arizona's participation in the Emergency Medical Services (EMS) Licensure Interstate Compact. It allows licensed EMTs, AEMTs, and paramedics from Arizona (the "home state") to practice in other participating states ("remote states") without obtaining new licenses, provided Arizona meets specific standards like requiring the national NREMT exam for initial licensure and sharing adverse actions. The compact requires member states to verify competency, share license-related disciplinary information, and maintain systems for cross-state recognition. This directly affects Arizona-licensed EMS personnel seeking to work temporarily in other member states and state EMS authorities managing licensure verification.
Arizona's HB 2248, titled the "Arizona Medical Freedom Act," bans businesses, schools, and government entities from requiring medical interventions (like vaccines or treatments) as a condition for services, employment, school attendance, or access to facilities. It specifically prohibits: denying services or entry based on vaccination status, requiring interventions for employment (except for foreign travel requirements), or offering different pay based on whether someone has received a medical intervention. The law includes exceptions for standard workplace safety equipment under industry standards (but excludes pandemic-era mandates like mask requirements) and does not apply to schools operating under parental rights laws. Violations can be enforced by the attorney general, who may seek court orders and recover legal fees.
SB 1095 prohibits health professionals in Arizona from providing gender transition procedures, irreversible gender reassignment surgery, or referrals for such procedures to individuals under 18 years old. The bill allows exceptions for medical conditions like disorders of sex development (e.g., XX virilization or XY undervirilization) or treatments for infections, injuries, or life-threatening conditions. It also bans the use of public funds for gender transition procedures for minors in state-run facilities or by state-employed health professionals. The law establishes disciplinary action for violations and allows individuals to seek legal remedies for noncompliance.
SB 1015 would make healthcare providers personally liable for costs related to detransition procedures (reversing gender transition) for minors within 25 years of the initial treatment. It allows minors to sue providers for injuries (including psychological harm) up to age 26, covering medical costs, pain and suffering, and attorney fees. The bill prohibits providers from using contracts to waive this liability, stating such waivers violate Arizona's public policy. This directly affects minors receiving gender transition care and the healthcare professionals providing it, imposing long-term financial and legal responsibility on providers.